IBB

iShares Biotechnology ETF

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Financial Services

industry

Asset Management

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Not Scheduled

Business Summary

The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.

 


Analyze IBB on TradingView

VALUATION

P/E

N/A

Market Cap ($M USD)

$8.02B

Forward P/E

N/A

PEG

N/A

PRICE TO SALES

N/A

PRICE TO BOOK

N/A

EV / EBITDA

N/A

5-Year Average P/E

Free Cash Flow Yield

N/A

DCF Value

N/A

Graham Number

N/A

Price to FCF

N/A

EV to FCF

N/A

Earnings Yield

N/A

FCF Yield

N/A

DIVIDEND

Yield

N/A

Annual Payout

N/A

Payout Ratio

N/A

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

N/A

Next Year EPS Growth Estimate

N/A

Next Year Revenue Growth Estimate

N/A

Return on Equity (ROE)

N/A

FREE CASH FLOW

Operating Margin

N/A

Debt-to-Equity

N/A

Piotroski F-Score

N/A

Altman Z-Score

N/A

Return on Invested Capital (ROIC)

N/A

Current Ratio

N/A

Quick Ratio

N/A

Net Debt to EBITDA

N/A

Interest Coverage

N/A

Gross Profit margin

N/A

FCF PER SHARE

N/A

REVENUE PER SHARE

N/A

Analyze IBB on TradingView

Gainseekers Quantitative Analysis

Summary

The absence of key valuation metrics like the Forward P/E, Earnings Yield, and Altman Z-score leaves a gaping hole in assessing IBB’s financial health. With no DCF Value or Graham Number available, the market’s pricing of this ETF remains an enigma. The snapshot price hovered above its 50-Day SMA, suggesting a potential technical overextension. However, the ETF’s beta of 0.74 indicates lower volatility, which might appeal to risk-averse investors. Overall, the lack of concrete financial data makes it challenging to definitively gauge its valuation.

AI Exposure / Tech Reliance

Operating within the asset management industry, IBB is uniquely positioned to leverage AI and tech advancements. As a biotechnology-focused ETF, it can capitalize on cutting-edge innovations in healthcare and life sciences. This adaptability could enhance its portfolio's resilience against tech-driven market shifts.

The Bull Case

For a value or GARP investor, IBB's appeal might lie in its sector exposure rather than specific financial metrics. Although traditional indicators like ROIC, FCF Yield, and Piotroski F-Score are missing, the ETF's focus on biotechnology offers potential for growth driven by scientific breakthroughs. Investors might view this as an opportunity to gain exposure to a sector poised for long-term innovation and expansion.

The Bear Case

The glaring lack of financial metrics such as Price/Book, Price/Sales, and cash flow indicators raises red flags for potential investors. With the ETF trading close to its 52-week high, there is a risk of overvaluation without clear earnings or cash flow support. This technical overextension, combined with the absence of concrete financial data, paints a picture of uncertainty and potential downside risk.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

N/A

Average Analyst Price Target

N/A

Institutional Ownership %

1-Year Beta

0.74

Insider Buying % (6 Mo)

Distance to 52-Week High

4.33%

Distance to 52-Week Low

29.43%

EARNINGS SURPRISE %

N/A

50-DAY SMA

$169.33

200-DAY SMA

$162.97

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.